Back to today’s briefing

Story perspectives

Retina Specialists Gradually Embrace Ranibizumab Biosimilars Amid Challenges

3/17/2025

33 6

Summary

Story summary

Retina specialists are slowly embracing ranibizumab biosimilars, despite cost-driven mandates like step therapy that restrict treatment options. As their familiarity with these alternatives grows, acceptance is rising. The anticipated arrival of aflibercept biosimilars may offer a more seamless integration, providing hope for effective age-related macular degeneration treatments amid challenging insurance landscapes.

1 of 1

Story summary

Retina specialists are slowly embracing ranibizumab biosimilars, despite cost-driven mandates like step therapy that restrict treatment options. As their familiarity with these alternatives grows, acceptance is rising. The anticipated arrival of aflibercept biosimilars may offer a more seamless integration, providing hope for effective age-related macular degeneration treatments amid challenging insurance landscapes.